Microrna-27b inhibitors
AssigneeNEUmiRNA Therapeutics Aps
InventorsMarkus Sakari Kauppinen, Stine Normann Hansen, Henrik Valdemar Klitgaard
Life of this patent
Estimating the term…
Abstract
The present invention provides antisense oligonucleotides complementary to miR-27b, capable of potently inhibiting the activity of miR-27b. Such compounds are useful as pharmaceuticals for treatment of diseases in the CNS or in the PNS including neurological diseases.
Claims16
An antisense oligonucleotide comprising a sequence of 18-19 nucleotides in length complementary to miR-27b, wherein the antisense oligonucleotide is a mixmer having from seven to 14 affinity-enhancing nucleotide analogues and does not contain a stretch of more than three contiguous DNA nucleotides, and wherein said antisense oligonucleotide comprises one to 18 phosphorothioate internucleoside linkages.
2-15. (canceled)
A method for the treatment, alleviation, amelioration, pre-emptive treatment or prophylaxis treatment of a miR-27b related disease of the CNS or PNS, said method comprising administrating to a subject in the need thereof an antisense oligonucleotide comprising a sequence of 18-19 nucleotides in length complementary to miR-27b, wherein the antisense oligonucleotide is a mixmer having from seven to 14 affinity-enhancing nucleotide analogues and does not contain a stretch of more than three contiguous DNA nucleotides, and wherein said antisense oligonucleotide comprises one to 18 phosphorothioate internucleoside linkages.
Dependencies are inferred from the claim text.